Brean Capital today maintained a Buy rating on Keryx Biopharmaceuticals (NASDAQ: KERX) with a price target of $15.00.

"We ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE